Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients

Starting soon · Phase 4

Conditions studied: MAGT1 Deficiency

In brief

This is a single-arm, open-label, single-center, exploratory clinical trial evaluating the safety and efficacy of decitabine in male patients aged 1 month to 18 years with X-linked magnesium transporter 1 (MAGT1) deficiency. Eligible patients have a confirmed MAGT1 gene mutation leading to XMEN disease ( X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect). The study will assess changes in liver function, immune function, and NKG2D expression, as well as adverse events, over four treatment cycles and the follow-up period.

Key facts

Study ID
NCT07555405
Run by
Children's Hospital of Fudan University
People needed
6
Starts
2026-04-01
Expected to finish
2028-12-01
Last updated by the study team
2026-04-29

Who can join

Age: 0 and older, up to 18. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.